Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BMY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BMY and 80,000+ other tickers.
See exactly how BMY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMY and 80,000+ other tickers.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial…
Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Don't catch a falling knife.
Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.